Whole-Blood Transcriptome Unveils Altered Immune Response in Acute Myocardial Infarction Patients With Aortic Valve Sclerosis.
Luca PiacentiniVeronika A MyasoedovaMattia ChiesaChiara VavassoriDonato MoschettaVincenza ValerioGloria GiovanettiIlaria MassaiuNicola CosentinoGiancarlo MarenziPoggio PaoloGualtiero Ivanoe ColomboPublished in: Arteriosclerosis, thrombosis, and vascular biology (2023)
Our findings shed light on the molecular mechanisms underlying AVSc and provide potential prognostic insights for patients with AMI with AVSc. During AMI, patients with AVSc showed increased type I IFN (interferon) response and earlier adverse cardiovascular outcomes. Novel pharmacological therapies aiming at limiting type I IFN response during or immediately after AMI might improve poor cardiovascular outcomes of patients with AMI with AVSc.
Keyphrases
- acute myocardial infarction
- aortic valve
- immune response
- dendritic cells
- percutaneous coronary intervention
- left ventricular
- transcatheter aortic valve replacement
- transcatheter aortic valve implantation
- aortic valve replacement
- aortic stenosis
- gene expression
- single cell
- acute coronary syndrome
- toll like receptor
- dna methylation
- atrial fibrillation
- single molecule
- adverse drug